This is the first part of a two-part paper that has arisen from the work of the IEEE Power Engineering Society's Multi-Agent Systems (MAS) Working Group.Part I of this paper examines the potential value of MAS technology to the power industry. In terms of contribution, it describes fundamental concepts and approaches within the field of multiagent systems that are appropriate to power engineering applications. As well as presenting a comprehensive review of the meaningful power engineering applications for which MAS are being investigated, it also defines the technical issues which must be addressed in order to accelerate and facilitate the uptake of the technology within the power and energy sector.
Part II of this paper explores the decisions inherent in engineering multi-agent systems for applications in the power and energy sector and offers guidance and recommendations on how MAS can be designed and implemented.Index Terms-Multi-agent systems.
T. (2007) Multi-agent systems for power engineering applicationspart 2: technologies, standards and tools for building multi-agent systems. IEEE Transactions on Power Systems, 22 (4). pp. 1753-1759.
Background
The pathophysiology of COVID-19 includes immune-mediated hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is among cytokines that contribute to the inflammatory processes. Lenzilumab, a GM-CSF neutralising monoclonal antibody, was investigated in the LIVE-AIR trial to assess its efficacy and safety in treating COVID-19 beyond available treatments.
Methods
In LIVE-AIR, a phase 3, randomised, double-blind, placebo-controlled trial, hospitalised adult patients with COVID-19 pneumonia not requiring invasive mechanical ventilation were recruited from 29 sites in the USA and Brazil and were randomly assigned (1:1) to receive three intravenous doses of lenzilumab (600 mg per dose) or placebo delivered 8 h apart. All patients received standard supportive care, including the use of remdesivir and corticosteroids. Patients were stratified at randomisation by age and disease severity. The primary endpoint was survival without invasive mechanical ventilation to day 28 in the modified intention-to-treat population (mITT), comprising all randomised participants who received at least one dose of study drug under the documented supervision of the principal investigator or sub-investigator. Adverse events were assessed in all patients who received at least one dose of study drug. This trial is registered with
ClinicalTrials.gov
,
NCT04351152
, and is completed.
Findings
Patients were enrolled from May 5, 2020, until Jan 27, 2021. 528 patients were screened, of whom 520 were randomly assigned and included in the intention-to-treat population. 479 of these patients (n=236, lenzilumab; n=243, placebo) were included in the mITT analysis for the primary outcome. Baseline demographics were similar between groups. 311 (65%) participants were males, mean age was 61 (SD 14) years at baseline, and median C-reactive protein concentration was 79 (IQR 41–137) mg/L. Steroids were administered to 449 (94%) patients and remdesivir to 347 (72%) patients; 331 (69%) patients received both treatments. Survival without invasive mechanical ventilation to day 28 was achieved in 198 (84%; 95% CI 79–89) participants in the lenzilumab group and in 190 (78%; 72–83) patients in the placebo group, and the likelihood of survival was greater with lenzilumab than placebo (hazard ratio 1·54; 95% CI 1·02–2·32; p=0·040). 68 (27%) of 255 patients in the lenzilumab group and 84 (33%) of 257 patients in the placebo group experienced at least one adverse event that was at least grade 3 in severity based on CTCAE criteria. The most common treatment-emergent adverse events of grade 3 or higher were related to respiratory disorders (26%) and cardiac disorders (6%) and none led to death.
Interpretation
Lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with CO...
The Strathprints institutional repository (https://strathprints.strath.ac.uk) is a digital archive of University of Strathclyde research outputs. It has been developed to disseminate open access research outputs, expose data about those outputs, and enable the management and persistent access to Strathclyde's intellectual output. In this paper the authors propose the integration of COMMAS and PEDA as a means of offering enhanced decision support to engineers tasked with managing transformer assets. By providing automatically interpreted data related to condition monitoring and power system disturbances, the proposed integrated system will offer engineers a more comprehensive picture of the health of a given transformer. Defects and deterioration in performance can be correlated with the operating conditions it experiences.The integration of COMMAS and PEDA has highlighted the issues inherent to the inter-operation of existing multi-agent systems and, in particular, the issues surrounding the use of differing ontologies. The authors believe that these issues will need to be addressed if there is to be widespread deployment of MAS technology within the power industry. This paper presents research undertaken to integrate the two MAS and to deal with ontology issues.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.